GeneDx Holdings Corp. (WGS)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
Research Workspace
Put WGS beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Achieve positive adjusted net income in 2026: GAAP EPS -0.60 vs consensus -0.19.
View ThesisRevenue is growing steadily — about 25% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens weak on capital allocation, the balance sheet, market reaction to earnings.
View ManagementExpectations look high — the market is pricing in about 97% growth a year, above the roughly 23% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 3% on a typical day and fell roughly 79% in its worst 12-month stretch.
View RiskWGS must achieve positive adjusted net income in 2026 to justify its price. Revenue grew 11% year over year, but the last quarter missed expectations. It trades at 5.6× price-to-sales, below the 5.7× peer median. The market expects more growth than we forecast, making the valuation look full. The primary risk is the latest earnings miss, which could lower estimates. Peer multiples imply a price about 97% below where it trades. This read is provisional.
Trailing returns as of 2026-09-04. WGS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 9 analysts currently covering WGS (as of Sep 2026).
Based on 3 Wall Street analysts offering 12-month price targets for WGS in the last 4 months.
Continue this research
Compare WGS with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| WGS Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 4 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Compare the value case
Put WGS next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Execution issues may hinder revenue growth objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $85.99
The last 12 months of price, then the range of analyst 12-month targets from today’s $85.99.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Disappointing Q1 results challenge growth and guidance.